The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy was equally exceptionally high in older and younger adults. These extremely encouraging trial results with a neoantigen vaccine may suggest the beginning of a paradigm shift in our view of the impact of immunosenescence on vaccination against novel infectious diseases.

中文翻译：

---

SARS-CoV-2疫苗在老年人中的出乎意料的功效

抗COVID-19疫苗的开发和测试速度之快是前所未有的。与传统的随机临床试验一样，许多研究都排除了老年人。但是，由于早已意识到老年人最容易感染COVID，因此在这些不寻常的情况下，老年人已被纳入许可试验。来自Comirnaty疫苗（BNT162b）试验的最新发表的结果出乎意料地证明，在老年人和年轻人中，疫苗功效同样异常高。这些关于新抗原疫苗的极令人鼓舞的试验结果可能表明，在我们认为免疫衰老对新型传染病疫苗接种的影响方面，范式的转变已经开始。